Top in rheumatology: Post-acute COVID-19 syndrome, gout treatment debate
Click Here to Manage Email Alerts
There are still more questions than answers regarding post-acute COVID-19 syndrome, despite mounting evidence documenting its existence, according to researchers.
An exploration on what is currently known about risk factors, pathogenesis and therapies for long COVID was the top story in rheumatology last week.
Another top story covered the gout “epidemic” and the controversies surrounding its management.
Read these and more top stories in rheumatology below:
Much about post-acute COVID-19 syndromes remains ‘poorly defined’
Despite a growing body of evidence documenting the existence of post-acute COVID-19 syndromes, there remain many more questions than answers, according to data presented at the Basic and Clinical Immunology for the Busy Clinician symposium. Read more.
'Horribly mismanaged': Debate over gout treatment rages as cases surge
All around the world, gout prevalence is growing at an alarming pace, while gout treatment remains as “horribly mismanaged” as ever. Read more.
FDA doubles initial Evusheld dosing regimen to enhance prevention of COVID-19 variants
The FDA has revised its emergency use authorization for the monoclonal antibody cocktail Evusheld (tixagevimab plus cilgavimab, AstraZeneca) doubling its initial dosing for COVID-19 prevention in light of data suggesting it may be less active against certain omicron subvariants. Read more.
Vertical integration secures PBMs as ‘arsonists and firefighters’ of drug prices
In the last 4 years, the three biggest pharmacy benefit managers have consolidated influence in the U.S. health care marketplace through vertical integration with insurance carriers. Read more.
Most rheumatologists 'unlikely' to switch to biosimilars until greater payer adoption
Despite an overwhelming majority of rheumatologists reporting comfort and familiarity with biosimilars, 65% said they are “unlikely” to switch their patients from reference products until there is greater payer adoption, according to data. Read more.